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Background: Chloroquine (CQ) and hydroxychloroquine (HCQ) are used to treat auto-immune related diseases
such as rheumatoid arthritis (RA) or systemic lupus erythematosus. Both drugs however can cause retinal toxicity
eventually leading to irreversible maculopathy and retinopathy. Established risk factors are duration and dosage of
treatment while the involvement of genetic factors contributing to toxic maculopathy is largely unclear. To address
the latter issue, this study aimed to expand on earlier efforts by (1) evaluating risk-altering variants known to be
associated with age-related macular degeneration (AMD), a frequent maculopathy in individuals over 55 years of
age, and (2) determining the contribution of genetic variants in the coding sequence of the ABCA4 gene.
Methods: The ABCA4 gene was analyzed by deep sequencing technology using a personal genome machine
(Ion Torrent) with 200 bp read length. Assessment of AMD variants was done by restriction enzyme digestion of
PCR products and TaqMan SNP genotyping. Effect sizes, p-values and confidence intervals of common variants were
evaluated by logistic regression (Firth’s bias corrected). To account for multiple testing, p-values were adjusted
according to the false discovery rate.
Results: We found no effects of known AMD-associated variants on the risk of toxic maculopathy. In contrast, we
report a statistically significant association of common variants in the ABCA4 gene with retinal disease, assessed by
a score-based variance-component test (PSKAT = 0.0055). This association remained significant after adjustment for
environmental factors like age and duration of medication and was driven by three common variants in ABCA4
(c.5682G > C, c.5814A > G, c.5844A > G), all conferring a reduced risk for toxic maculopathy.
Conclusions: Our findings demonstrate that minor alleles of common genetic variants in ABCA4 significantly
reduce susceptibility to develop toxic maculopathy under CQ treatment. A refined risk profile based on genetic and
environmental factors may have implications for revised recommendations in CQ as well as HCQ treatment.
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Genetic associationBackground
Chloroquine (CQ) and hydroxychloroquine (HCQ) are
chemical compounds frequently used to treat auto-immune
related diseases such as rheumatoid arthritis (RA) or sys-
temic lupus erythematosus. Side effects of the treatment in-
clude gastrointestinal problems, itching and headaches and,
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unless otherwise stated.induced retinal toxicity, the latter eventually leading to irre-
versible maculopathy and retinopathy. The prevalence of
CQ-induced maculopathy (herein referred to as toxic
maculopathy) has been reported to be between 10% and
25% for patients treated with CQ and between 0.5% and
7.5% after HCQ therapy [1-4]. So far, there is no treatment
addressing the drug-related side effects.
The initial symptom of toxic retinal damage is pericen-
tral relative scotoma in the automated threshold perim-
etry. If the drug is not discontinued at this early phase,
the characteristic bulls-eye shaped alterations of thetral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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acuity and absolute (peri-)central scotoma.
Recently, potential risk factors for toxic maculopathy
due to HCQ treatment have been investigated in a large
collection of patients [4]. The authors conclude that dur-
ation of use, daily doses of the drug as well systemic kid-
ney disease and concurrent tamoxifen citrate therapy are
risk factors for toxic maculopathy. Furthermore, this study
proposed to use real body weight instead of ideal body
weight to calculate the daily dose of HCQ, since real body
weight predicted the risk for toxic maculopathy better
than ideal body weight. In an earlier retrospective study
including 51 patients treated with CQ or HCQ, age and
the duration of intake were suggested as major risk factors
for toxic maculopathy [5]. Although a timely diagnosis of
toxic retinal damage by adhering to the screening guide-
lines of the American Academy of Ophthalmology [6] is
highly warranted, Nika et al. [7] showed that even in a
health-insured population many high risk patients are not
screened regularly for toxic side effects of the treatment.
So far, there are only few clues as to a contribution of
genetic factors to the risk of toxic maculopathy. One study
found that two out of eight patients with toxic maculopa-
thy carried monoallelic mutations in ABCA4 [8], a gene in
which mutations have been associated with autosomal re-
cessive Stargardt disease [9] and the genetically complex
age-related macular degeneration [10,11]. Interestingly,
mutations in ABCA4 were also implicated to cause heredi-
tary bull’s eye maculopathy (BEM) [12,13], a phenotype
reminiscent of toxic maculopathy.
The exact mechanism of retinotoxicity of CQ and HCQ is
not clear; however, cell culture studies and animal model ex-
periments suggest a possible adverse effect on lysosomal
function and subsequent lipofuscin accumulation [14,15].
Lipofuscin appears to be toxic for photoreceptors as well as
RPE cells and may be causal to degenerative processes in
retinal diseases such as Stargardt’s disease or age-related
macular degeneration (AMD) [16,17].
Here, we expand on previous efforts to evaluate variants
in the ABCA4 gene for their potential contribution to
toxic maculopathy [8]. We analyzed the ABCA gene in a
sample of 37 patients treated with CQ of which 24 had
and 13 had not developed toxic maculopathy at the time
of the study. Our cohort did not include patients with
HCQ-induced maculopathy.
We sequenced the 50 coding exons and the immediate
flanking intronic sequences of the ABCA4 gene and com-
pared the findings to publicly available data obtained in
267 European individuals from the 1000 Genomes Project.
Since toxic maculopathy shares phenotypic similarities
with AMD such as central macular degeneration and lipo-
fuscin accumulation, we also investigated the impact of
genetic risk factors known to be associated with AMD.
Therefore, we genotyped toxic maculopathy patients andcontrols for ten common AMD risk variants and calculated
a genetic risk score according to Grassmann et al. [18].
Knowledge about genetic factors conferring susceptibil-
ity to toxic maculopathy could help to identify patients at
greater risk to develop toxic side effects when treated with




This study followed the tenets of the Declaration of Hel-
siniki and was approved by the ethics committee of the
Charité (Ethikkommission der Charité – Universitätsme-
dizin Berlin; date of approval: 12.1.2010; application
number: EA2/100/09). All subjects gave informed con-
sent to participate in the study.
Medical records of the patients who presented at the De-
partment of Ophthalmology at the Charite Hospital between
2000 and 2010 were reviewed retrospectively for evaluation
of retinal damage due to CQ treatment. To be classified as a
case, patients had to exhibit unequivocal macular and func-
tional alterations (i.e. bull’s eye maculopathy on funduscopy
and/ or optical coherence tomography and/ or fundus auto-
fluorescence imaging, pericentral scotoma in the automated
threshold perimetry, pericentrally decreased amplitudes in
the multifocal electroretinogram). To be classified as a con-
trol, CQ-treated patients revealed no signs of macular dam-
age based on any of the aforementioned clinical criteria.
Patients which could not be classified unanimously as
affected or unaffected by toxic maculopathy or which re-
vealed macular alterations of possibly other aetiology (like
age-related macular degeneration) were excluded from the
study.
Patients eligible for the study were contacted via phone
or mail and asked for participation. Risk factors as postu-
lated by the American Academy of Ophthalmology [6]
were inquired. Furthermore, patients on CQ treatment
during the period between January 2010 and December
2013 were directly included in the study at the time of
presentation at the Ophthalmology Department.
Ophthalmologic findings, data on medication history
and risk factors were generally considered at the time of
initial presentation or when a definitive ophthalmologic
diagnosis was made.
Genotyping of AMD-associated risk variants
We genotyped ten AMD associated risk variants in six gene
loci according to the parsimonic risk model of Grassmann
et al. [18]. Genotyping of single nucleotide polymorphisms
(SNPs) was achieved by restriction enzyme digestion of PCR
products (RFLP) and TaqMan SNP Genotyping (Applied
Biosystems, Foster City, USA) as described previously [18].
We coded each genotype as number of risk increasing al-
leles (0, 1 or 2) and computed the risk score with the
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“a” was chosen as 8.97, which is the mean genetic risk score
calculated from these ten variants in 267 European samples
in the 1000 Genomes Project (Release 20110521, http://
www.1000genomes.org, accessed 2 May 2012).
Sequencing of the ABCA4 gene and data analysis
DNA was extracted as previously described [18]. To amp-
lify the 50 coding ABCA4 exons and their immediate
flanking intronic sequences a custom-made STGD1
MASTR Assay (Multiplicom, Niel, Belgium) was used.
The multiplexed PCR fragments of each patient were
pooled equimolarly and processed using the Ion Xpress™
Plus Fragment Library kit (Life Technologies) according to
the manufacturers recommendations. We used the Ion
Xpress™ Barcode Adapters 1–16 to allow for multiplexing
of DNA libraries. The resulting DNA libraries were puri-
fied with AMPure beads (Beckman Coulter), and their
concentrations and sizes were determined on an Agilent
BioAnalyzer DNA high-sensitivity Chip (Agilent Tech-
nologies). Between 5 and 10 libraries were pooled equimo-
larly and sequenced in one sequencing run. Emulsion PCR
and enrichment of cDNA-conjugated particles were per-
formed with the Ion OneTouch™ 200 Template Kit v2 DL
(Life Technologies) according to the manufacturer’s in-
structions. The final particles were loaded on an Ion 316
chip and sequenced with a Personal Genome Machine
(Ion Torrent) with 200 bp read length (Life Technologies).
Reads were aligned to the ABCA4 reference (NM_000
350.2) using the CLC Genomics Workbench (http://
www.clcbio.com). Coverage per exon and minimum
coverage per coding base were recorded. In order to as-
sure sufficient power to detect variants, the minimum
coverage threshold of a coding base was set to 30. Frag-
ments failing this threshold were re-sequenced with the
Sanger sequencing chain termination method. Variants
were called with the Probablistic Variant Caller in CLC.
We excluded called variants in intronic regions beyond
10 bp within the donor and acceptor splice sites, re-
spectively. A genotype was coded as the number of
minor alleles at a given variant (0, 1 or 2).
To compare obtained allele frequencies with a larger refer-
ence sample, we extracted the genotypes of all variants for
267 EUR samples in the 1000 Genomes Project (Interim Re-
lease 20110521) and coded the genotype according to the
number of minor alleles.
Statistical analysis
To evaluate whether variants in ABCA4 jointly (common
and rare; protective and adverse) are associated with toxic
maculopathy, the genotype matrix containing the identi-
fied ABCA4 variants was analysed with a SNP-set (Se-
quencing) Kernel Association Test (SKAT) in R [19] using
the functions SKAT_Null_Model and SKAT_CommonRarewith standard settings from the package “SKAT” [20]. We
fit two baseline models (null models), one without any co-
variates (unadjusted model) and one including age, gender,
duration of medication (in months) and daily dose per ideal
body weight (in mg/kg) as covariates (adjusted model). In
order to assess whether rare or common or both variants
are responsible for the observed association, we used the op-
tions test.type = “Rare.Only” and test.type = “Common.Only”.
The cut-off frequency threshhold for “rare” and “common”
was assessed by CommonRare_Cutoff = 1/√(2*sample size).
Logistic regression was used to evaluate the effect size,
p-values and confidence intervals of common genetic
variants in ABCA4 as well as AMD associated variants.
The association of clinical variables with disease risk was
assess by the two-sided student’s t-test. To adjust the as-
sociation of genetic variants for clinical variables like
treatment duration or daily dose per ideal body weight,
we used Firth’s bias reduced logistic regression for small
sample sizes [21] implemented in the R package logistf
[22]. Multiple testing was accounted for by adjusting the
observed raw p-values according to the false discovery
rate (FDR) [23].
Results
Twenty-four patients with toxic maculopathy and 13 pa-
tients with no signs of maculopathy after CQ treatment
were included in the study. A summary characteristics of
the patient population is given in Table 1. We first evaluated
the differences of clinical risk factors between patients with
(cases) and those without (controls) toxic maculopathy after
CQ treatment. Cases were significantly older than controls
and were exposed to a higher average daily dose per ideal
body weight (Pt-test < 0.05). Then, we investigated the effect
of ten common AMD-associated variants on the risk of
toxic maculopathy. The results of the unadjusted logistic
regression analysis are summarized in Additional file 1:
Table S1 demonstrating that no statistically significant asso-
ciation of known AMD-associated variants with CQ-
induced maculopathy was detected. Additionally, a genetic
risk score [18] was computed and was −0.43 (SD: 1.32) for
cases and 0.20 (SD: 1.06) for controls. This association is sta-
tistically not significant (Pt-test = 0.148).
To investigate the contribution of variants in ABCA4 on
toxic maculopathy risk, we sequenced the 50 ABCA4 exons
and their immediate flanking intronic sequences in the 37
patients treated with CQ. In total, we identified 23 ABCA4
variants in the 37 CQ-treated patients and, after extraction
of the genotypes for the 267 EUR samples from the 1000
Genomes project (if present), the frequencies in the three
groups were computed (Table 2).
To assess whether the identified variants in ABCA4
jointly are associated with toxic maculopathy, we used
SKAT on the resulting genotype matrix of variants found
in cases and controls. Variants were considered “rare” if
Table 1 Summary characteristics of CQ-treated patients
Cases* Controls† p-value (two-sided t-test)
Number of Individuals 24 13 -
Mean Age (S.D.) [years] 61.18 (10.45) 49.11 (9.74) 0.0016
Treatment Duration (S.D.) [months] 153.1 (97.77) 121.8 (58.74) 0.2327
Daily dose per body weight (S.D.) [mg/kg] 4.00 (1.26) 3.90 (0.84) 0.7966
Daily dose per ideal weight (S.D.) [mg/kg] 4.90 (1.25) 4.07 (0.31) 0.0078
Fraction of Individuals > 60 years 0.71 0.15 -
Male [%] 0.04 0.23 0.1622
*Patients treated with CQ and affected with toxic maculopathy.
†Patients treated with CQ and no signs of toxic maculopathy.
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was lower than 11.6% (i.e. lower than 1/√(2*sample size)).
A statistically significant association of this SNP set with
CQ-induced maculopathy was found (PSKAT = 0.0055).
This association remained statistically significant after
adjusting the baseline SKAT model for gender, treatment
duration (in months), age (in years) and daily dose perTable 2 Genetic variants identified in ABCA4 sequence analys
(controls) toxic maculopathy
Variant (NM_000350.2) Amino acid exchange (NP_000341.2)
c.324G > A M114I
c.635G > A R212H
c.1268A > G* H423R
c.1269C > T H423H
c.1622T > C L541P
c.2588G > C G863A
c.2828G > A R943Q
c.3113C > T A1038V
c.4203C > A P1401P
c.4297G > A V1433I
c.5603A > T N1868I
c.5682G > C* L1894L
c.5814A > G* L1938L
c.5843C > T P1948L
c.5844A > G* P1948P
c.6069T > C I2023I
c.6148G > C V2050L
c.6249C > T I2083I
c.6282 + 7G > A -
c.6285T > C D2095D
c.6357A > G E2119E
c.6730-3T > C -
c.6764G > T S2255I
*Common variants (combined frequency in cases and controls > 11.6%).
†Frequency in 267 European individuals obtained from the 1000 Genomes Project.
#False discovery rate.ideal weight (in mg/kg) (PSKAT = 0.025). This effect ap-
pears to be driven by common variants (i.e. variants with a
frequency above 11.6%). We observed a statistically signifi-
cant association when restricting the SKAT model to com-
mon variants (PSKAT = 0.005 for the unadjusted model,
PSKAT = 0.008 for the adjusted model), while we failed to
find significance for rare variants (PSKAT = 0.223 for theis in CQ-treated patients with (cases) and without
Frequency in
Cases Controls EUR† Raw p-value FDR#
0.00 0.04 - - -
0.06 0.08 0.06 - -
0.29 0.23 0.30 0.58783 0.58783
0.13 0.04 0.07 - -
0.02 0.00 - - -
0.00 0.04 0.00 - -
0.04 0.12 0.04 - -
0.02 0.00 0.00 - -
0.00 0.04 - - -
0.00 0.04 0.00 - -
0.06 0.08 0.07 - -
0.13 0.38 0.26 0.02292 0.030
0.06 0.31 0.18 0.00722 0.014
0.04 0.08 0.04 - -
0.06 0.31 0.19 0.00722 0.014
0.04 0.08 0.06 -
0.02 0.00 0.00 - -
0.04 0.08 0.05 - -
0.04 0.08 0.05 - -
0.08 0.15 0.10 - -
0.02 0.00 - - -
0.02 0.12 0.02 - -
0.02 0.12 0.02 - -
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We therefore limited the further statistical evaluation to var-
iants with a combined frequency above 11.6% in cases and
controls (indicated by an asterisk in Table 2). This revealed a
statistically significant association of three synonymous vari-
ants (c.5682G >C, c.5814A >G, c.5844A >G) after adjust-
ment for multiple testing (false discovery rate < 0.05). The
frequencies for these variants differed by more than 20% be-
tween cases and controls (Table 2) and showed a protective
effect, i.e. odds ratios smaller than one (Table 3). We also in-
vestigated whether this association was independent of CQ
dosage, age and gender and computed logistic regression
models for each SNP adjusted jointly for age, gender, dur-
ation of treatment and daily dose per ideal body weight. We
found a consistent (and significant) protective effect for
these variants indicating an independent association with
toxic maculopathy (Table 3).
When comparing cases with EUR samples, we again
found statistically significant odds ratios smaller than one
(Table 3) for all three protective variants. Two variants
(c.5814A >G and c.5844A >G) are in high linkage disequi-
librium with r2 = 0.95 based on the CEU (Northern and
Western European ancestry) reference panel in the 1000
Genomes Project (http://1000genomes.org). These vari-
ants therefore represent the same risk haplotype and
should confer the risk jointly.
The associated variants (c.5682G >C, c.5814A >G, c.5
844A >G) represent synonymous alterations with no obvi-
ous effect on amino acid composition of the ABCA4 trans-
porter. Two of these (c.5682G >C and c.5844A >G)
influence codon usage and each result in about 50% less
frequently used codons [24]. Variant c.5682G >C changes
the codon from CTG (3.99%) to CTC (1.96%) and c.5844A
>G changes the codon from CCA (1.69%) to CCG (0.69%).
In contrast, c.5814A >G changes the codon from TTA
(0.77%) to TTG (1.29%), a more frequently used codon.
Discussion
This study aimed to further explore a potential influence
of genetic variants on the risk of developing toxic macu-
lopathy after prolonged CQ treatment. First, we evalu-
ated a possible association of known AMD-associatedTable 3 Sensitivity analysis of significantly associated variant
Cases vs. Controls
Variant OR (95% CI#), unadjusted model OR (9
c.5682G > C 0.30 (0.09-0.85) 0.05 (0
c.5814A > G 0.16 (0.03-0.63) 0.01 (0
c.5844A > G 0.16 (0.03-0.63) 0.01 (0
*Adjusted jointly for age, gender, treatment duration and daily dose per ideal body
†Patients treated with CQ and affected with toxic maculopathy were compared to d
#Confidence intervals.variants on disease risk but found no statistically signifi-
cant evidence for this hypothesis. However, our analysis
can not exclude that other as yet unknown AMD-
associated variants may play a role in the etiology of
toxic maculopathy or that our patient cohort may lack
statistical power to detect significant differences with
minor effects.
We then assessed the ABCA4 gene and identified genetic
variants significantly associated with CQ-induced maculopa-
thy. This association is mainly driven by three common vari-
ants (c.5682G >C, c.5814A >G and c.5844A >G), whose
minor alleles confer increased protection from the toxic
maculopathy. While the study provides robust and signifi-
cant association data, the sample size of 37 patients is rela-
tively small in principle due to the rarity of toxic
maculopathy but also to the fact that nowadays CQ is less
frequently used for therapeutic purposes than HCQ which
possible shows reduced side effects with regard to
treatment-induced pathology. Even more challenging is the
recruitment of control subjects who received CQ but never
developed maculopathy under this treatment. Considering
the limited number of available cases and controls in this
study, it is obvious that our statistical evaluation had to be
limited to common variants while rare variant analysis
would have lacked sufficient statistical power. In fact, our
study design would theoretically require at least 200 cases
and controls to obtain a moderate power of 21% to detect a
significant association with a set of rare variants (PSKAT <
0.05 with a minor allele frequency below 0.03).
A comparison to Shroyer et al. [8], a study which included
a total of only 8 patients suffering from toxic maculopathy
upon CQ treatment, showed a deleterious effect of ABCA4
variants on disease risk and appears to suggest a contradic-
tion to our findings. In this report, however, patient #7 car-
ried three pathologic mutations known to be associated with
Stargardt disease (Arg2107His and Leu1201Arg/Arg2107His
in a cis configuration). As a consequence, this patient
may rather be appreciated as manifesting Stargardt disease
than toxic CQ-associated maculopathy. Considering the
remaining 7 CQ-related maculopathy patients, the frequen-
cies of the minor (in our study protective) ABCA4 variants
are 0.29, 0.14 and 0.14 for c.5682G >C, c.5814A >G ands
Cases vs. EUR†
5% CI#), adjusted model* OR (95% CI#), unadjusted model
.00 - 1.00) 0.43 (0.16-0.94)
.00 - 0.27) 0.32 (0.08-0.91)
.00 - 0.27) 0.29 (0.07-0.80)
weight.
ata from 267 European individuals obtained from the 1000 Genomes Project.
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those in our data set in the CQ-associated maculopathy
cases but clearly lower than our controls and thus reveal a
similar orientation of effect for these three polymorphic
alleles.
The odds ratios per ABCA4 risk allele indicate a
strong risk reduction of risk-altering allele carriers to-
wards toxic maculopathy. Two variants in ABCA4
(c.5814A > G and c.5844A > G) are in close proximity to
each other demonstrating strong linkage disequilibrium.
It is therefore likely that the two variants represent a
common associated (protective) haplotype. A larger pa-
tient sample size will be needed to statistically determine
the true toxic maculopathy-associated variant, c.5814A
> G or c.5844A > G. It should be emphasized that the
range of risk reduction of the toxic maculopathy-
associated ABCA4 variants is well comparable to odds
ratios of non-risk alleles at the CFH or ARMS2/HTRA1
loci, two genomic regions which are considered to be
strongly associated with large effect sizes with the devel-
opment of AMD [25].
Although synonymous variants are commonly regarded
as benign in their effects towards disease, they have the
potential to affect RNA stability and RNA splicing and can
influence the rate of protein translation and thus protein
conformation [26-29]. Associations of synonymous vari-
ants with complex phenotypes are not unusual and this
could call for a paradigm shift when considering the func-
tional impact of these variants on disease and complex
traits. Alternatively, other so far unknown variants in link-
age disequilibrium with the identified synonymous vari-
ants may influence disease risk by altering splicing or by
influencing transcription levels due to reduced transcrip-
tion factor (enhancer) binding. Ultimately, to determine
the functional variants at the ABCA4 locus which could
be responsible for a protective effect on toxic maculopa-
thy, more in-depth studies in cellular or animal model sys-
tems will be required.
Since our study lacks sample size to reliably evaluate risk
scores and project absolute risk estimates, we cannot at
present evaluate the combined effect of these genetic vari-
ants with or without other risk factors like age or duration
of treatment. However, it is expected that these factors to-
gether with genetic data will result in an excellent risk pre-
diction accuracy and therefore be deemed important to be
evaluated in a larger study despite the given constraints on
patient recruitment as discussed above. For instance, the
National Eye Institute (NEI) is currently recruiting pa-
tients for a clinical trial (NCT01145196) to assess the im-
pact of ABCA4 mutations on toxic maculopathy risk.
Should this knowledge of protective genetic variants
have an influence on clinical practice? The ABCA4-ana-
lysis in any patient who is about to receive CQ would gen-
erally be desirable. As this analysis is not covered by thehealth insurance the patient himself has to bear the finan-
cial burden. Therefore, if recommended, it should most
likely be done primarily in CQ patients with a non-genetic
high-risk profile, i.e. in older patients with a high dose per
body weight, high body mass index, restriction of excre-
tory liver and renal function or in patients whose eyesight
is reduced due to other reasons. If the combined genetic
and non-genetic profile indicates a high risk, another
disease-modifying drug might be preferred. In principle,
phenotypes and non-genetic risk factors of CQ and HCQ
maculopathy are similar. Therefore, the results of the
present study may be projected onto HCQ maculopathy.
A recent study found an overall prevalence of 7.5% for
HCQ-induced maculopathy [4], which further emphasizes
the medical need to treat patients based on an individual
risk profil for possible side effects. Further and larger sized
studies will be needed to replicate the current findings,
specifically in patients treated with HCQ, a drug nowadays
replacing CQ.
Conclusions
Taken together, our findings demonstrate that minor alleles
of common genetic variants in ABCA4 significantly reduce
susceptibility to develop toxic maculopathy under CQ
treatment. A refined risk profile based on genetic and envir-
onmental factors may have implications for revised recom-
mendations in CQ as well as HCQ treatment. As our
approach was targeted to include candidate genes upon a
sophisticated guess as to their possible relation with the dis-
ease, it would be desirable to extend the genetic analyses to
a genome-wide unbiased screening approach. This would
allow to decipher the full genetic spectrum of CQ-and hope-
fully HCQ-induced maculopathy.
Additional file
Additional file 1: Table S1. Association results for 10 known AMD
associated variants using single logistic regression in patients treated
with chloroquine.
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